Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Ranibizumab on Microvasculature, Oxidative Stress and Recurrence in Primary Pterygium Surgery
NCT04878835Phase 1Completed
- Sponsor
- Universiti Sains Malaysia
- Start
- May 2018
- Primary completion
- Apr 2020
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of ranibizumab in pterygium (2 arms), sponsored by Universiti Sains Malaysia. Primary endpoint: Microvascular Density at 2 weeks. Started May 2018; status: completed.
02
Drugs
ranibizumab
03
Conditions
pterygium
Beyond the preview
Go deeper on NCT04878835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04878835.